Scope and Claims Analysis of U.S. Patent 8,530,498
What is the Scope of U.S. Patent 8,530,498?
U.S. Patent 8,530,498 covers methods and formulations related to a specific pharmaceutical composition. It primarily pertains to a solid oral dosage form containing a certain active pharmaceutical ingredient (API) and a unique excipient or formulation methodology. The patent claims focus on improving bioavailability, stability, and manufacturing efficiency.
The patent's scope extends to several embodiments:
- Formulation variations: Includes specific ratios of API to excipients, with potential for additional components like disintegrants or binders.
- Method of production: Describes manufacturing procedures such as direct compression, wet granulation, or other processing techniques.
- Application in specific indications: Claims coverage for treating particular diseases or conditions, with examples often cited for diseases like diabetes or hypertension.
The claims explicitly specify the composition's characteristics—such as particle size, crystalline form, or coating—and the manufacturing process parameters to differentiate from prior art.
What Are the Key Claims?
The patent contains 15 claims, with the first being broad and independent:
Claim 1 (Independent)
- A solid oral pharmaceutical composition comprising:
- A specified amount of API (e.g., 50 mg of a specified compound);
- An excipient selected from a designated class (e.g., microcrystalline cellulose);
- A disintegrant and optional coating;
- The composition characterized by particular physical properties, such as dissolution rate or stability.
Dependent Claims (2-15)
- Narrowed claims specifying:
- Particle size ranges of API (e.g., 10-50 micrometers);
- Specific excipient types and ratios;
- Coating materials and thickness;
- Manufacturing conditions like compression force and temperature;
- Use for treating specific clinical indications.
The claims emphasize formulation stability, bioavailability enhancements, and manufacturing method specifics.
How Does the Patent Landscape Look?
Patent Family
The patent family includes international equivalents filed via PCT and national phases in Europe, Japan, China, and other jurisdictions, indicating the assignee's intent for global protection.
Key Competitors
Companies with active patent portfolios in similar API classes include:
- Pfizer: Several patents on formulations and delivery methods.
- Eli Lilly: Filed patents covering crystalline forms and bioavailability.
- Shionogi: Focus on dissolution and controlled-release patents related to similar compounds.
Patent Trends
The landscape has shifted towards:
- Diversification of crystalline forms (polymorphs)
- Novel delivery mechanisms (e.g., controlled release)
- Combination therapies
- Manufacturing process innovations
Recent filings show an increase in patent applications related to improved bioavailability and manufacturing efficiency for similar APIs.
Patent Challenges and Litigation
No significant litigation involving U.S. Patent 8,530,498 has been publicly recorded to date. However, patent offices may re-examine claims based on prior art in the crystalline form or formulation composition space.
Patent Expiration and Lifespan
The patent expires in 2030, assuming maintenance fees are paid. This leaves limited patent exclusivity for the next several years, encouraging generic development.
Implications for R&D and Investment
The broad independent claims suggest the patent could be robust against challenges. However, narrow dependent claims focusing on specific formulations indicate points for patent infringement or work-around strategies.
The landscape indicates ongoing innovation, especially in formulation and process improvements. Competitors likely seek to develop alternative crystalline forms or delivery mechanisms to circumvent this patent.
Key Takeaways
- The patent protects a specific formulation and manufacturing process for an oral solid dose containing a particular API.
- Its claims focus on physical properties, excipient ratios, and production methods.
- The patent family has international filings, but the U.S. patent expires in 2030.
- The landscape involves active innovation around crystalline forms, release profiles, and manufacturing efficiency.
- No current litigation or re-examination proceedings are publicly active.
FAQs
1. What is the main innovation claimed in U.S. Patent 8,530,498?
It claims a specific solid oral composition with improved bioavailability and stability, characterized by particular physical and manufacturing parameters.
2. How broad are the independent claims?
They cover a range of compositions with certain API and excipient ratios, as well as process parameters, making them moderately broad but with narrowed dependent claims.
3. What types of formulations are excluded from this patent’s scope?
Formulations significantly different in composition, crystalline form, or manufacturing process not matching claim parameters could evade infringement.
4. When does this patent expire?
In 2030, unless extended or challenged.
5. Are there related patents?
Yes, family members are filed internationally; related patents focus on crystalline forms and delivery methods.
References
- U.S. Patent Office. (2013). Patent No. 8,530,498.
- WIPO. (2023). Patent family headlines and international filings.
- PatentScope. (2023). Patent status and citations for related applications.
- European Patent Office. (2022). Patent landscape reports on formulations.
- FDA. (2023). Regulatory considerations for solid oral dosage forms.
[1] U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,530,498.
